演題抄録

一般口演

開催概要
開催回
第56回・2018年・横浜
 

当院における切除不能再発進行胃癌に対するramucirumab+paclitaxelの使用経験

演題番号 : O28-4

[筆頭演者]
演者)柳田 茂寛:1 
[共同演者]
有上 貴明:1、松下 大輔:1、川越 浩輔:1、大久保 啓史:1、貴島 孝:1、天辰 仁彦:1、夏越 祥次:1

1:鹿児島大学・消化器・乳腺甲状腺外科

 

Background: Ramucirumab (RAM) is a monoclonal antibody VEGFR-2 antagonist and RAINBOW phase 3 trial revealed RAM with paclitaxel (PTX) (RAM/PTX) significant improvement of overall survival compared with placebo plus PTX. Thus RAM/PTX has been recommended standard 2nd line regimen in cases with metastatic or unresectable gastric cancer. Purpose: To clarify which cases have possible good response to RAM/PTX by review the cases treated with RAM/PTX in our hospital, retrospectively. Cases: 36 cases treated with RMA/PTX form December 2013 to July 2017 were enrolled in this study. Results: Patients backgrounds were as follows: Male/female;22/14, Age 65 ≦ / 65>; 18/18, differentiated/undifferentiated; 15/21, HER2 positive/negative; 14/22, recurrence/unresectable; 11/25, peritoneal metastasis/liver metastasis was 19/8, the administration line 2nd-3rd/4th≦; 29/7, The administration cycle 3≧/4≦; 27/9, The best evaluation of RAM/PTX PR/SD/PD; 2/5/29, and the response and disease control rate was 5.5% and 19.4%, respectively. Regarding side effect grade 3 or higher, 13 cases with neutropenia, and 2cases anemia and appetite loss. Infusion reaction and proteinuria (3+) occurred in one case, respectively. The median progression free survival was 5.5 months (range: 2.2-23.4). Cases without peritoneal metastasis and those with liver metastasis had significant good response (35%; p=0.0184, 63%; 0.0012), respectively. All 7 cases of the administration line with 4th or later had no response to RAM/PTX (p=0.-647). Conclusion: RAM/PTX is useful regimen in cases with liver metastasis and without peritoneal metastasis in our hospital. But the administration line should be early as recommended by guideline.

キーワード

臓器別:胃・十二指腸

手法別:化学療法

前へ戻る